Amelie\u00ae is the commercial brand name of Almonertinib Mesilate Tablets, an orally active third-generation EGFR tyrosine kinase inhibitor developed by Jiangsu Hansoh Pharmaceutical Group. It selectively inhibits EGFR activating mutations and the T790M resistance mutation to block downstream tumor cell signaling pathways.<\/p>\n\n\n\n
Main Indications<\/strong> Common Side Effects<\/strong> Approval Status in China<\/strong> Buy Amelie (Almonertinib Mesilate Tablets)\u00a0online from China and save up to 80% on costs . no insurance needed . compare prices from a certified HongKong pharmacy .with fast shipping. Contact us now on WhatsApp to get the latest prices.<\/p>\n\n\n\n <\/p>\n","protected":false},"excerpt":{"rendered":" Amelie\u00ae is the commercial brand name of Almonertinib Mesilate Tablets, an orally active third-generation EGFR tyrosine kinase inhibitor developed by Jiangsu Hansoh Pharmaceutical Group. It selectively inhibits EGFR activating mutations and the T790M resistance mutation to block downstream tumor cell signaling pathways. Main IndicationsTreatment of adult patients with locally advanced or metastatic non-small cell lung […]<\/p>\n","protected":false},"author":4,"featured_media":3898,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[101],"tags":[],"class_list":["post-3897","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-drug-news"],"blocksy_meta":[],"yoast_head":"\n
Treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring EGFR T790M mutation, who have progressed on prior EGFR-TKI therapy.<\/p>\n\n\n\n
Common mild adverse reactions: Diarrhea, rash, pruritus, stomatitis and fatigue.
Laboratory abnormalities: Elevated liver enzymes, hypokalemia and decreased neutrophil count.
Severe but uncommon risks: Interstitial lung disease, severe diarrhea, hepatotoxicity and ocular toxicities.<\/p>\n\n\n\n
Amelie\u00ae (Almonertinib Mesilate Tablets, 55mg) was officially approved for marketing in China in 2020. It is currently a prescription anti-tumor drug included in China\u2019s Category B medical insurance.<\/p>\n\n\n\n